Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hemoglobin01:24

Hemoglobin

Hemoglobin is a globular protein made up of four subunits. Two of these subunits are alpha chains, and the other two are beta chains. Each subunit contains a molecule of heme, which has an iron atom and can bind to oxygen. When an oxygen molecule binds to one heme group, it changes the shape of hemoglobin, making it easier for the other heme groups to bind oxygen as well.
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...
Oxygen Transport in the Blood01:27

Oxygen Transport in the Blood

Hemoglobin (Hb) is a crucial molecule in the human body, consisting of four polypeptide chains, each bound to an iron-containing heme group. This unique structure enables hemoglobin to bind to oxygen, with each molecule capable of combining with four molecules of oxygen, leading to rapid and reversible oxygen loading. When fully loaded with oxygen, it is called oxyhemoglobin, while hemoglobin that has released oxygen is called reduced hemoglobin or deoxyhemoglobin. As hemoglobin binds oxygen,...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LOW-VOLUME RESUSCITATION WITH VS -101, A NEXT-GENERATION PEGYLATED HEMOGLOBIN-BASED OXYGEN CARRIER, IMPROVES SURVIVAL AFTER SEVERE HEMORRHAGIC SHOCK IN RATS.

Shock (Augusta, Ga.)·2025
Same author

EXCHANGE TRANSFUSION WITH VS -101: A NEW PEGYLATED-HB DESIGNED TO RESTORE PERFUSION AND INCREASE O 2 CARRYING CAPACITY.

Shock (Augusta, Ga.)·2023
Same author

How Nitric Oxide Hindered the Search for Hemoglobin-Based Oxygen Carriers as Human Blood Substitutes.

International journal of molecular sciences·2023
Same author

Characterizing cell interactions at scale with made-to-order droplet ensembles (MODEs).

Proceedings of the National Academy of Sciences of the United States of America·2022
Same author

High diversity droplet microfluidic libraries generated with a commercial liquid spotter.

Scientific reports·2021
Same author

Systemic and microvascular comparison of Lactated Ringer's solution, VIR-HBOC, and alpha-alpha crosslinked haemoglobin-based oxygen carrier in a rat 10% topload model.

Artificial cells, nanomedicine, and biotechnology·2020

Related Experiment Video

Updated: Jun 3, 2026

Synthesis, Hemoglobin Encapsulation and Biorthogonal PEGylation in Hierarchically Porous UiO-66 Nanoparticles for Oxygen Delivery Applications
09:24

Synthesis, Hemoglobin Encapsulation and Biorthogonal PEGylation in Hierarchically Porous UiO-66 Nanoparticles for Oxygen Delivery Applications

Published on: May 8, 2026

MP4, a vasodilatory PEGylated hemoglobin.

Russell H Cole1, Kim D Vandegriff

  • 1Sangart Inc., 6175 Lusk Blvd., San Diego, CA 92121, USA. russell.cole@gmail.com

Advances in Experimental Medicine and Biology
|March 30, 2011
PubMed
Summary

This study introduces MP4, a novel hemoglobin-based oxygen carrier (HBOC) using polyethylene glycol (PEG) conjugation. MP4 demonstrates vasodilatory effects by decoupling nitric oxide scavenging from vascular response, offering potential therapeutic benefits.

More Related Videos

Exploring Alternative Perfusion Solutions Using Next-Generation Polymerized Hemoglobin-Based Oxygen Carriers in a Model of Rat Ex Vivo Lung Perfusion
09:47

Exploring Alternative Perfusion Solutions Using Next-Generation Polymerized Hemoglobin-Based Oxygen Carriers in a Model of Rat Ex Vivo Lung Perfusion

Published on: June 14, 2024

Related Experiment Videos

Last Updated: Jun 3, 2026

Synthesis, Hemoglobin Encapsulation and Biorthogonal PEGylation in Hierarchically Porous UiO-66 Nanoparticles for Oxygen Delivery Applications
09:24

Synthesis, Hemoglobin Encapsulation and Biorthogonal PEGylation in Hierarchically Porous UiO-66 Nanoparticles for Oxygen Delivery Applications

Published on: May 8, 2026

Exploring Alternative Perfusion Solutions Using Next-Generation Polymerized Hemoglobin-Based Oxygen Carriers in a Model of Rat Ex Vivo Lung Perfusion
09:47

Exploring Alternative Perfusion Solutions Using Next-Generation Polymerized Hemoglobin-Based Oxygen Carriers in a Model of Rat Ex Vivo Lung Perfusion

Published on: June 14, 2024

Area of Science:

  • Biomedical Engineering
  • Cardiovascular Research
  • Oxygen Therapeutics

Background:

  • Hemoglobin-based oxygen carriers (HBOCs) are being developed as blood substitutes.
  • Some HBOCs exhibit vasoconstrictive properties due to nitric oxide (NO) scavenging.
  • Understanding HBOC mechanisms is crucial for therapeutic applications.

Purpose of the Study:

  • To investigate the vasodilatory mechanisms of a novel PEGylated HBOC, MP4.
  • To explore how MP4's properties decouple NO scavenging from vascular response.
  • To elucidate the role of high oxygen affinity and surface chemistry in MP4's function.

Main Methods:

  • Surface conjugation of polyethylene glycol (PEG) to tetrameric human hemoglobin (Hb) to create MP4.
  • Analysis of NO-binding kinetics and oxygen affinity (p50) of MP4.
  • Evaluation of MP4's interaction with endothelial cells and its effect on vascular permeability.
  • Assessment of hemodynamic responses in vivo.

Main Results:

  • MP4 exhibits high oxygen affinity (p50 = 5 mmHg), potentially minimizing ATP interference with intravascular ATP signaling.
  • PEGylation of Hb may reduce endothelial permeability, similar to unconjugated PEG.
  • PEGylation of MP4 may enhance nitrite reductase activity, promoting bioactive NO production.
  • MP4 demonstrated favorable hemodynamic responses in vivo.

Conclusions:

  • MP4's vasodilatory effect is attributed to decoupled NO scavenging, high oxygen affinity, and unique surface chemistry.
  • PEGylation of Hb offers a promising strategy for developing safer and more effective HBOCs.
  • MP4 shows potential as a therapeutic agent for oxygen delivery with improved vascular function.